Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CART Cells”

177 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 177 results

Testing effectiveness (Phase 2)Looking for participantsNCT07471789
What this trial is testing

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Who this might be right for
Acute Myeloblastic LeukaemiaLeukemia, T-Cell
Gyala Therapeutics 33
Not applicableNot Yet RecruitingNCT07008872
What this trial is testing

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Who this might be right for
CD7+ LymphomaCD7+ Acute Leukemia
Qi deng 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04430595
What this trial is testing

Multi-4SCAR-T Therapy Targeting Breast Cancer

Who this might be right for
Breast Cancer
Shenzhen Geno-Immune Medical Institute 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06739226
What this trial is testing

Combination Immunotherapy Targeting Melanoma

Who this might be right for
Melanoma
Shenzhen Geno-Immune Medical Institute 30
Not applicableLooking for participantsNCT05621291
What this trial is testing

Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Who this might be right for
B-AllAcute Lymphoblastic Leukemia
National Cancer Institute (NCI) 60
Not applicableUnknownNCT05745454
What this trial is testing

A Clinical Study on the Safety and Efficacy of Chimeric Antigen Receptor T-cell (CART) in the Treatment of Solid Tumors

Who this might be right for
Solid Tumor
su haichuan 12
Not applicableUnknownNCT02097381
What this trial is testing

Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy

Who this might be right for
HIV Infection
University of Roma La Sapienza 10
Early research (Phase 1)Active Not RecruitingNCT03635632
What this trial is testing

C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)

Who this might be right for
Relapsed NeuroblastomaRefractory NeuroblastomaRelapsed Osteosarcoma+4 more
Baylor College of Medicine 94
Early research (Phase 1)Looking for participantsNCT06732492
What this trial is testing

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

Who this might be right for
NK T-Cell LymphomaCART TherapyCD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Testing effectiveness (Phase 2)Looking for participantsNCT04544592
What this trial is testing

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

Who this might be right for
B-cell Acute Lymphoblastic LeukemiaB-cell Non Hodgkin Lymphoma
University of Colorado, Denver 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04016129
What this trial is testing

CAR-T Immunotherapy Targeting CD19- ALL

Who this might be right for
B-cell Leukemia
Shenzhen Geno-Immune Medical Institute 100
Very early researchNot Yet RecruitingNCT06298266
What this trial is testing

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital 15
Early research (Phase 1)UnknownNCT04480788
What this trial is testing

CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Who this might be right for
T Lymphoblastic Leukemia/LymphomaExtramedullary NK-T-cell Lymphoma, Nasal TypePeripheral T-cell Lymphoma, Nonspecific+4 more
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 9
Testing effectiveness (Phase 2)Looking for participantsNCT07681596
What this trial is testing

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AstraZeneca 101
Testing effectiveness (Phase 2)Looking for participantsNCT07538635
What this trial is testing

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Who this might be right for
High-risk R/R LBCL
Zhejiang Cancer Hospital 20
Early research (Phase 1)Looking for participantsNCT05656573
What this trial is testing

CART-PSMA Cells for Advanced Prostate Cancer

Who this might be right for
Prostate Cancer
Nova Therapeutics LLC 20
Early research (Phase 1)Looking for participantsNCT06709469
What this trial is testing

Phase I Clinical Trial of CART Cell Therapy for Refractory/Relapsed Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults

Who this might be right for
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Instituto de Investigación Hospital Universitario La Paz 10
Testing effectiveness (Phase 2)Looking for participantsNCT07271121
What this trial is testing

Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ Relapsed
King Hussein Cancer Center 26
Very early researchUnknownNCT04184414
What this trial is testing

The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaMantle Cell LymphomaFollicular Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Next Page